Drugs / GSK3003895A
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01905215 | Jul 2013 → Apr 2014 | respiratory syncytial virus infectious disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT02360475 | Mar → Jul 2015 | respiratory syncytial virus infectious disease | GlaxoSmithKline | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GSK3003895A | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01905215 ↗ |
| Modality | Vaccine | “RSV vaccine GSK3003895A (formulation 3)” NCT01905215 ↗ |
| Route | Intramuscular | “Intramuscular (IM) vaccination in the deltoid region of the non-dominant arm at Day 0 according to protocol schedule” NCT01905215 ↗ |